Literature DB >> 24697323

Soluble epoxide hydrolase inhibitor, t-TUCB, protects against myocardial ischaemic injury in rats.

Ayush Shrestha1, Praveen T Krishnamurthy, Pooja Thomas, Bruce D Hammock, Sung H Hwang.   

Abstract

OBJECTIVES: To determine the protective role of a soluble epoxide hydrolase(sEH) inhibitor, trans-4-{4-[3-(4-trifluoromethoxyphenyl)-ureido] cyclohexyloxy} benzoic acid (t-TUCB), in isoproterenol (ISO)-induced myocardial ischaemic injury in vivo.
METHODS: Cardioprotective activity of t-TUCB was studied against ISO-induced myocardial ischaemic injury in male Wistar rats. Cardioprotection was assessed by measuring elecrocardiographic (EKG), serum lactate dehydrogenase (LDH) and creatine kinase (CK-MB) levels, cardiac calcium and antioxidant levels, and also by measuring infarct size in the cardiac tissue. KEY
FINDINGS: Pretreatment with t-TUCB at 3, 10 and 30 mg/kg orally for a period of 14 days significantly prevented the changes in EKG parameters (QTc interval prolongation, ST height depression, pathological Q waves formation and T-wave inversion), serum cardiac biomarkers (CK-MB and LDH), relative heart weight, myocardial calcium levels, infarct size and the oxidative status in the cardiac tissue (lipid peroxidation, catalase and superoxide dismutase levels) when compared with the untreated control animals (P < 0.05).
CONCLUSION: The sEH inhibitor t-TUCB significantly prevents ISO-induced myocardial ischaemic injury in rats. This study provides a preliminary confirmation of the efficacy of t-TUCB by oral administration in rats.
© 2014 Royal Pharmaceutical Society.

Entities:  

Keywords:  ischaemic injury; isoproterenol (ISO); soluble epoxide hydrolase inhibitor; t-TUCB

Mesh:

Substances:

Year:  2014        PMID: 24697323      PMCID: PMC4134728          DOI: 10.1111/jphp.12251

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  31 in total

1.  Mechanisms by which epoxyeicosatrienoic acids (EETs) elicit cardioprotection in rat hearts.

Authors:  Garrett J Gross; Anna Hsu; John R Falck; Kasem Nithipatikom
Journal:  J Mol Cell Cardiol       Date:  2007-01-10       Impact factor: 5.000

Review 2.  Soluble epoxide hydrolase inhibitors: a patent review.

Authors:  Hong C Shen
Journal:  Expert Opin Ther Pat       Date:  2010-07       Impact factor: 6.674

Review 3.  Review article: epoxyeicosatrienoic acids: novel mediators of cardioprotection.

Authors:  Kasem Nithipatikom; Garrett J Gross
Journal:  J Cardiovasc Pharmacol Ther       Date:  2010-03-03       Impact factor: 2.457

4.  Epoxyeicosatrienoic acids attenuate reactive oxygen species level, mitochondrial dysfunction, caspase activation, and apoptosis in carcinoma cells treated with arsenic trioxide.

Authors:  Liu Liu; Chen Chen; Wei Gong; Yuanjing Li; Matthew L Edin; Darryl C Zeldin; Dao Wen Wang
Journal:  J Pharmacol Exp Ther       Date:  2011-08-16       Impact factor: 4.030

Review 5.  The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases.

Authors:  Xizhen Xu; Xin A Zhang; Dao Wen Wang
Journal:  Adv Drug Deliv Rev       Date:  2011-04-06       Impact factor: 15.470

6.  Orally bioavailable potent soluble epoxide hydrolase inhibitors.

Authors:  Sung Hee Hwang; Hsing-Ju Tsai; Jun-Yan Liu; Christophe Morisseau; Bruce D Hammock
Journal:  J Med Chem       Date:  2007-07-06       Impact factor: 7.446

7.  Epoxyeicosatrienoic acid prevents postischemic electrocardiogram abnormalities in an isolated heart model.

Authors:  S N Batchu; E Law; D R Brocks; J R Falck; J M Seubert
Journal:  J Mol Cell Cardiol       Date:  2008-10-10       Impact factor: 5.000

8.  Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation.

Authors:  Jun-Yan Liu; Hsing-Ju Tsai; Sung Hee Hwang; Paul D Jones; Christophe Morisseau; Bruce D Hammock
Journal:  Br J Pharmacol       Date:  2009-01-13       Impact factor: 8.739

Review 9.  Cardioprotection: a radical view Free radicals in pre and postconditioning.

Authors:  Claudia Penna; Daniele Mancardi; Raffaella Rastaldo; Pasquale Pagliaro
Journal:  Biochim Biophys Acta       Date:  2009-02-24

10.  Non-urea functionality as the primary pharmacophore in soluble epoxide hydrolase inhibitors.

Authors:  Sampath-Kumar Anandan; Zung N Do; Heather K Webb; Dinesh V Patel; Richard D Gless
Journal:  Bioorg Med Chem Lett       Date:  2009-01-10       Impact factor: 2.823

View more
  11 in total

1.  Inhibitors of soluble epoxide hydrolase minimize ischemia-reperfusion-induced cardiac damage in normal, hypertensive, and diabetic rats.

Authors:  Oliul Islam; Prashanth Patil; Sumanta K Goswami; Rema Razdan; Mohammed N Inamdar; Mohammed Rizwan; Jubin Mathew; Bora Inceoglu; Kin S Stephen Lee; Sung H Hwang; Bruce D Hammock
Journal:  Cardiovasc Ther       Date:  2017-06       Impact factor: 3.023

2.  Possible role of Epoxyeicosatrienoic acid in prevention of oxidative stress mediated neuroinflammation in Parkinson disorders.

Authors:  Navya Lakkappa; Praveen T Krishnamurthy; Bruce D Hammock; D Velmurugan; M M Srinivas Bharath
Journal:  Med Hypotheses       Date:  2016-06-05       Impact factor: 1.538

3.  Inhibition of soluble epoxide hydrolase attenuates eosinophil recruitment and food allergen-induced gastrointestinal inflammation.

Authors:  Idil Bastan; Xiao Na Ge; Mythili Dileepan; Yana G Greenberg; Alonso G Guedes; Sung Hee Hwang; Bruce D Hammock; Robert J Washabau; Savita P Rao; P Sriramarao
Journal:  J Leukoc Biol       Date:  2018-01-17       Impact factor: 4.962

Review 4.  Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics.

Authors:  John D Imig
Journal:  Pharmacol Ther       Date:  2018-06-30       Impact factor: 12.310

5.  Inhibition of soluble epoxide hydrolase increases coronary perfusion in mice.

Authors:  Jun Qin; Dong Sun; Houli Jiang; Sharath Kandhi; Ghezal Froogh; Sung Hee Hwang; Bruce D Hammock; Michael S Wolin; Carl I Thompson; Thomas H Hintze; An Huang
Journal:  Physiol Rep       Date:  2015-06

6.  Deletion of soluble epoxide hydrolase attenuates mice Hyperoxic acute lung injury.

Authors:  Li-Ping Liu; Bin Li; Tian-Kui Shuai; Lei Zhu; Yu-Min Li
Journal:  BMC Anesthesiol       Date:  2018-04-27       Impact factor: 2.217

7.  Soluble epoxide hydrolase inhibitors, t-AUCB, downregulated miR-133 in a mouse model of myocardial infarction.

Authors:  Yajun Gui; Da Li; Jingyuan Chen; Yating Wang; Jiahui Hu; Caixiu Liao; Limin Deng; Qunyan Xiang; Tao Yang; Xiao Du; Shilan Zhang; Danyan Xu
Journal:  Lipids Health Dis       Date:  2018-05-29       Impact factor: 3.876

Review 8.  Soluble Epoxide Hydrolase Inhibition to Face Neuroinflammation in Parkinson's Disease: A New Therapeutic Strategy.

Authors:  Mercè Pallàs; Santiago Vázquez; Coral Sanfeliu; Carles Galdeano; Christian Griñán-Ferré
Journal:  Biomolecules       Date:  2020-05-01

9.  Inhibition of Soluble Epoxide Hydrolase Limits Mitochondrial Damage and Preserves Function Following Ischemic Injury.

Authors:  Maria K Akhnokh; Feng Hua Yang; Victor Samokhvalov; Kristi L Jamieson; Woo Jung Cho; Cory Wagg; Abhijit Takawale; Xiuhua Wang; Gary D Lopaschuk; Bruce D Hammock; Zamaneh Kassiri; John M Seubert
Journal:  Front Pharmacol       Date:  2016-06-07       Impact factor: 5.810

10.  Soluble epoxide hydrolase inhibitors, t-AUCB, regulated microRNA-1 and its target genes in myocardial infarction mice.

Authors:  Ya-Jun Gui; Tao Yang; Qiong Liu; Cai-Xiu Liao; Jing-Yuan Chen; Ya-Ting Wang; Jia-Hui Hu; Dan-Yan Xu
Journal:  Oncotarget       Date:  2017-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.